Key result
Circulating biomarkers aid risk stratification and therapy monitoring in infective endocarditis, with troponin elevated in ~84%.
Why the study?
Infective endocarditis carries high morbidity and mortality and lacks a specific biomarker for early detection, prompting this review of the role of biomarkers in its diagnosis and management.
Although no single specific biomarker exists for early detection of infective endocarditis, circulating inflammatory, cardiac, and coagulation biomarkers serve as valuable adjuncts to clinical and imaging findings for diagnosis, monitoring treatment response, and risk stratification.
Answers are grounded in this paper and cite their sources.
May support adjunctive monitoring in infective endocarditis; leaves open prospective validation before routine use.
Infective endocarditis (IE) is a serious and potentially life-threatening disease, associated with high morbidity and mortality rates. This narrative review explores the role of biomarkers in the diagnosis and management of IE. Relevant literature was identified through a targeted search of major medical databases focusing on key biomarkers linked to this condition. Although no specific biomarker exists for the early detection of IE, inflammatory markers such as C-reactive protein (CRP), erythrocyte sedimentation rate, procalcitonin (PCT), and interleukin-6 (IL-6) reflect systemic immune activation and correlate with disease activity and response to therapy. Cardiac biomarkers, including troponins and natriuretic peptides (NT-proBNP), provide insight into myocardial involvement and hemodynamic stress, while coagulation markers like D-dimer are associated with thromboembolic risk. These biomarkers complement clinical and imaging findings by aiding in diagnosis, monitoring therapeutic response, and assessing prognosis. Emerging biomarkers, such as S100A11 and aquaporin-9, show promising potential for future clinical applications but require further research and validation.
No takes yet. Share an insight, caveat, or question.
BADEA et al. (2026) conducted a review in Infective endocarditis. Circulating inflammatory, cardiac, coagulation, and emerging proteomic/transcriptomic biomarkers (including CRP, procalcitonin, troponins, NT-proBNP, D-dimer, Cystatin C, IL-6, LRG1, NDUFB4, MR-proADM) vs. Standard diagnostic criteria (2023 Duke-ISCVID criteria, blood cultures, and cardiac imaging) was evaluated on Diagnosis, therapeutic response monitoring, and prognostic risk stratification in infective endocarditis. Circulating biomarkers such as CRP, procalcitonin, D-dimer, NT-proBNP, and troponins aid in risk stratification and therapy monitoring in infective endocarditis.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: